no anticoagulation

OTHER3 trials

Sponsors

University of North Carolina, Chapel Hill, Vantive Health LLC, University of Vermont

Conditions

Acute Kidney InjuryBlood ClotCancerContinuous Renal Replacement Therapy (CRRT)Regional Citrate Anticoagulation (RCA)VTE (Venous Thromboembolism)

Phase 3

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

TerminatedNCT02860130

Vantive Health LLCAcute Kidney Injury, Continuous Renal Replacement Therapy (CRRT), Regional Citrate Anticoagulation (RCA)

Start: 2016-09-27End: 2018-05-12Updated: 2025-07-22

DOAC - Dosing Options in AntiCoagulation Prophylaxis

RecruitingNCT07005024

University of VermontCancer, VTE (Venous Thromboembolism)

Start: 2025-10-17End: 2035-08-01Target: 996Updated: 2026-02-05

Unknown Phase

A Prospective Pharmacodynamic Study of Rivaroxaban

CompletedNCT01743898

University of North Carolina, Chapel HillBlood Clot

Start: 2012-10-31End: 2014-08-31Target: 65Updated: 2014-08-04